Pacific Biosciences of California(US:PACB) zacks.comยท2024-05-23 14:02Core Viewpoint - Pacific Biosciences of California (PACB) has shown significant stock performance, returning +36% over the past month, outperforming the S&P 500 composite's +6.1% and the Zacks Medical - Instruments industry's +6.9% [2] Earnings Estimate Revisions - The company is expected to report a loss of $0.23 per share for the current quarter, reflecting a year-over-year change of +11.5% [5] - The consensus earnings estimate for the current fiscal year is -$0.91, indicating a year-over-year change of +18%, with a recent change of +8.8% over the last 30 days [5] - For the next fiscal year, the consensus estimate is -$0.75, showing a change of +17.5% from the previous year, although this estimate has decreased by -10.7% recently [6] - The Zacks Rank for Pacific Biosciences is 3 (Hold), indicating a neutral outlook based on earnings estimate revisions [7] Revenue Growth Forecast - The consensus sales estimate for the current quarter is $40.4 million, representing a year-over-year decline of -15.1% [10] - The sales estimates for the current and next fiscal years are $176.32 million and $231.05 million, indicating changes of -12.1% and +31%, respectively [10] Last Reported Results and Surprise History - In the last reported quarter, Pacific Biosciences generated revenues of $38.81 million, a slight year-over-year decrease of -0.2% [11] - The EPS for the same period was -$0.26, compared to -$0.31 a year ago, with a revenue surprise of +0.08% against the Zacks Consensus Estimate [11] - Over the last four quarters, the company has surpassed consensus EPS estimates three times and topped revenue estimates each time [12] Valuation - Pacific Biosciences is graded D on the Zacks Value Style Score, indicating it is trading at a premium compared to its peers [16]